Skip to main content
KNSA
NASDAQ Life Sciences

CEO Converts Over $42M in Class B Shares to Class A

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$46.7
Mkt Cap
$2.173B
52W Low
$26.27
52W High
$59.87
52W Position info
78% above low
Off High info
22% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

KNSA sits 78% above its 52-week low of $26.27.

Summary

CEO Sanj K. Patel converted 900,000 Class B shares into Class A shares, a transaction valued at over $42 million, restructuring a significant portion of his equity holdings.


Key Events · Ownership and Investor Activity · KNSA

  • CEO Converts Shares

    Chairman and CEO Sanj K. Patel converted 900,000 Class B Ordinary Shares into Class A Ordinary Shares on June 1, 2026.

  • Significant Value

    The acquired Class A shares are valued at over $42 million, representing a substantial portion of the company's market capitalization.

  • Ownership Restructuring

    This conversion changes the form of the CEO's equity holdings, increasing his direct ownership of the publicly traded Class A shares.


Analysis · KNSA · Life Sciences

Sanj K. Patel, Chairman and CEO, converted 900,000 Class B Ordinary Shares into Class A Ordinary Shares, a transaction valued at over $42 million. This action restructures a significant portion of the CEO's equity holdings into the publicly traded Class A shares. While not a new cash investment, the conversion of such a large block of shares by the top executive is a notable administrative and ownership event, potentially impacting liquidity and voting rights associated with his holdings.

How filings like this one have moved

In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KNSA was trading at $46.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $26.27 to $59.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KNSA - Latest Insights

KNSA
Jul 28, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $79.95
Real-time Price: $75.15 info
Change: -$4.80 (-6%) info
Market Cap: $5.864B info
KNSA
Jul 28, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $63.30
Real-time Price: $75.15 info
Change: +$11.85 (+19%) info
Market Cap: $5.864B info
KNSA
Jul 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $63.30
Real-time Price: $75.15 info
Change: +$11.85 (+19%) info
Market Cap: $5.864B info
KNSA
May 26, 2026, 5:04 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $52.86
Real-time Price: $75.15 info
Change: +$22.29 (+42%) info
Market Cap: $5.864B info
KNSA
May 26, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $52.86
Real-time Price: $75.15 info
Change: +$22.29 (+42%) info
Market Cap: $5.864B info